The recommended dose for adults is 1200 mg administered in two divided doses 30 minutes before the morning and evening meals (see CLINICAL PHARMACOLOGY).
There have been reported cases of overdosage with gemfibrozil. In one case, a 7-year-old child recovered after ingesting up to 9 grams of gemfibrozil. Symptoms reported with overdosage were abdominal cramps, abnormal liver function tests, diarrhea, increased CPK, joint and muscle pain, nausea and vomiting. Symptomatic supportive measures should be taken, should an overdose occur.
Gemfibrozil Tablets USP 600 mg: White, elliptical, film-coated, scored tablets, imprinted ‘C17′ on one side, are available as follows:
NDC 75834-131-60: Bottles of 60
NDC 75834-131-18: Bottles of 180
NDC 75834-131-05: Bottles of 500
Store at controlled room temperature 20° – 25°C (68° – 77°F) [see USP]. Protect from light and humidity.
Manufactured for :
Nivagen Pharmaceuticals, Inc.
Sacramento, CA 95827
Toll free number : 1-877-977-0687
Manufactured by : Cadila Pharmaceuticals Ltd. 1389, Dholka, Dist. Ahmedabad, Gujarat State, India.
|GEMFIBROZIL gemfibrozil tablet|
|Labeler — Denton Pharma, Inc. DBA Northwind Pharmaceuticals (080355546)|
|Registrant — Denton Pharma, Inc. DBA Northwind Pharmaceuticals (080355546)|
|Denton Pharma, Inc. DBA Northwind Pharmaceuticals||080355546||repack (70934-466)|
Revised: 03/2020 Denton Pharma, Inc. DBA Northwind Pharmaceuticals
RxDrugLabels.com provides trustworthy package insert and label information about marketed prescription drugs as submitted by manufacturers to the U.S. Food and Drug Administration. Package information is not reviewed or updated separately by RxDrugLabels.com. Every individual prescription drug label and package insert entry contains a unique identifier which can be used to secure further details directly from the U.S. National Institutes of Health and/or the FDA.